Solventum (NYSE:SOLV) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Solventum (NYSE:SOLV) from a buy rating to a hold rating in a research report sent to investors on Sunday morning.

A number of other research analysts also recently issued reports on the company. Mizuho set a $100.00 price objective on Solventum and gave the company an “outperform” rating in a research note on Tuesday, January 20th. Wells Fargo & Company lowered their target price on Solventum from $86.00 to $83.00 and set an “equal weight” rating on the stock in a research note on Friday, February 27th. KeyCorp increased their price target on shares of Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. UBS Group restated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Solventum in a research report on Friday, February 27th. Seven analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $93.70.

Solventum Stock Down 1.5%

SOLV opened at $67.57 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. The company’s 50-day moving average is $77.14 and its 200 day moving average is $76.13. Solventum has a fifty-two week low of $60.70 and a fifty-two week high of $88.20. The firm has a market capitalization of $11.72 billion, a P/E ratio of 7.62, a PEG ratio of 1.12 and a beta of 0.40.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Research analysts expect that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its Board of Directors has initiated a share buyback plan on Thursday, November 20th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 7.5% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

Hedge Funds Weigh In On Solventum

Several large investors have recently modified their holdings of SOLV. United Services Automobile Association purchased a new stake in shares of Solventum during the 1st quarter valued at approximately $239,000. Woodline Partners LP raised its holdings in Solventum by 40.7% during the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock valued at $888,000 after acquiring an additional 3,377 shares during the period. Intech Investment Management LLC raised its holdings in Solventum by 167.0% during the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after acquiring an additional 10,425 shares during the period. Resona Asset Management Co. Ltd. lifted its position in shares of Solventum by 2.0% during the second quarter. Resona Asset Management Co. Ltd. now owns 49,786 shares of the company’s stock worth $3,773,000 after acquiring an additional 971 shares in the last quarter. Finally, Aviva PLC boosted its holdings in shares of Solventum by 6.8% in the second quarter. Aviva PLC now owns 103,452 shares of the company’s stock worth $7,846,000 after acquiring an additional 6,545 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.